Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Claya vs Framework

Claya
Graded #268

Lower grade

vs+2.299999999999997
Framework
Graded #230

Higher grade

The verdict

Framework takes it — 65.1/100 to 62.8/100.

Framework grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Framework is a personalized-plan GLP-1 telehealth platform offering compounded semaglutide and tirzepatide with doctor-guided treatment selection.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFramework +38
42
80
Dose & formulationClaya +11
75
64
Clinical oversightClaya +10
82
72
Labs & monitoringClaya +1
53
52
FulfillmentClaya +10
67
57
Contract termsClaya +20
61
41
Claya · left barFramework · right bar

The numbers

MetricClayaFramework
WeighScore62.8/10065.1/100
GradeCC
Scorecard rank#268#230
Semaglutide$299/mo (compounded)$100/mo (starting dose, compounded)
Tirzepatide$299/mo (compounded)$100/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Claya

Graded #268 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
Framework

Graded #230 · C

Strengths

  • Named 503B pharmacy partner (The Pharmacy Hub) disclosed — the FDA-registered outsourcing-facility pathway, distinct from 503A
  • Publishes the FDA compounded-medication disclaimer
  • $25/week pricing (~$100/mo) is among the most aggressive in the directory
  • $0 membership fees
  • Phone support published, toll-free (888) 412-0666

Where it loses points

  • LegitScript ID / certification not shown on the homepage
  • States-served list not disclosed
  • Medical director / clinical leadership not disclosed
  • Corporate legal entity not disclosed (no footer copyright)
  • Governing law / arbitration venue not stated

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard